EUVIMEDOpdag EUVIMED
Übersichtsarbeit

Linaclotide for irritable bowel syndrome with constipation: integrating realworld evidence into the therapeutic puzzle

K Argyriou, A Manolakis, E Tsakiridou, D Christodoulou, A Kapsoritakis, M Miltiadis

Acta Gastro Enterologica Belgica · 2026-03-30 · 91 (1) · 65

DOI: 10.51821/89.1.14529 ↗

At a glance

Übersichtsarbeit in Acta Gastro Enterologica Belgica, published online on 2026-03-02. Written by K Argyriou and 5 co-authors. Institution: Department of Gastroenterology, Medical School and University Hospital of Larissa, Larissa GR41334, Greece.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Irritable bowel syndrome with constipation (IBS-C) is a common subtype of functional bowel disorder associated with substantial symptom burden and reduced quality of life. Management typically begins with dietary and lifestyle modification, laxatives, and antispasmodics; however, many patients experience inadequate relief, underscoring the need for more effective therapies. Linaclotide, a synthetic guanylin analog, is an established treatment for IBS-C. By activating guanylate cyclase-C (GCC) receptors on intestinal epithelial cells, it promotes intestinal fluid secretion, accelerates transit, and alleviates visceral hypersensitivity. Randomized controlled trials have demonstrated its efficacy and favorable safety profile, with mild-to-moderate diarrhea and abdominal pain being the most common adverse events. Because clinical trial populations may not fully reflect real-world patient diversity, real-world evidence (RWE) provides valuable complementary data. This review summarizes current RWE on linaclotide in IBS-C, integrating findings from multiple studies to present a comprehensive view of its effectiveness and safety in routine clinical practice.

Subjects

Author keywords

constipationguanylate cyclase receptorguanylinirritable bowel syndromelinaclotide

Authors and institutions

  • Department of Gastroenterology, Medical School and University Hospital of Larissa, Larissa GR41334, Greece.
  • Medical School and University Hospital of Larissa, Larissa GR41334, Greece.
  • Department of Gastroenterology, Medical School and University Hospital of Ioannina, Ioannina GR45500, Greece.

Cite

APA

Argyriou, K., Manolakis, A., Tsakiridou, E., Christodoulou, D., Kapsoritakis, A., & Miltiadis, M. (2026). Linaclotide for irritable bowel syndrome with constipation: integrating realworld evidence into the therapeutic puzzle. Acta Gastro Enterologica Belgica, 91(1), 65. https://doi.org/10.51821/89.1.14529

Vancouver

Argyriou K, Manolakis A, Tsakiridou E, Christodoulou D, Kapsoritakis A, Miltiadis M. Linaclotide for irritable bowel syndrome with constipation: integrating realworld evidence into the therapeutic puzzle. Acta Gastro Enterologica Belgica. 2026;91(1):65. doi:10.51821/89.1.14529

BibTeX
@article{Argyriou2026,
  author = {Argyriou, K and Manolakis, A and Tsakiridou, E and Christodoulou, D and Kapsoritakis, A and Miltiadis, M},
  title = {Linaclotide for irritable bowel syndrome with constipation: integrating realworld evidence into the therapeutic puzzle},
  journal = {Acta Gastro Enterologica Belgica},
  year = {2026},
  volume = {91},
  number = {1},
  pages = {65},
  doi = {10.51821/89.1.14529}
}
Start for free →